- $8.80bn
- $9.04bn
- $1.98bn
- 92
- 31
- 60
- 65
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.34 | ||
| PEG Ratio (f) | 0.35 | ||
| EPS Growth (f) | 99.24% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.47 | ||
| Price to Tang. Book | 10.5 | ||
| Price to Free Cashflow | 17.52 | ||
| Price to Sales | 4.45 | ||
| EV to EBITDA | 30.02 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 1.9% | ||
| Return on Equity | 2.27% | ||
| Operating Margin | 4.94% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,870.35 | 2,251.66 | 2,141.52 | 1,965.31 | 1,978.21 | 2,034.06 | 2,165.07 | 5.32% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +158.75 | +15.16 | -13.33 | -19.18 | -58.84 | +224.67 | +8.52 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Directors
- Lawrence Rosen CSU (63)
- Thierry Bernard CEO (56)
- Roland Sackers CFO (53)
- Metin Colpan IND (66)
- Ross Levine IND (49)
- Elaine Mardis IND (58)
- Elizabeth Tallett IND (72)
- Thomas Ebeling SUB
- Toralf Haag SUB (55)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- April 29th, 1996
- Public Since
- September 1st, 1996
- No. of Employees
- 5,800
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 216,116,102
- Address
- Hulsterweg 82, VENLO, 5912 PL
- Web
- https://www.qiagen.com/
- Phone
- +31 773556600
- Contact
- Domenica Martorana
- Auditors
- KPMG AG Wirtschaftsprufungsgesellschaft
Latest News for QGEN
Upcoming Events for QGEN
Q1 2025 Qiagen NV Earnings Release
Q1 2025 Qiagen NV Earnings Call (Dutch)
Qiagen NV at BNP Paribas European CEO Conference
Qiagen NV at Goldman Sachs Global Healthcare Conference
Qiagen NV Annual Shareholders Meeting
Q2 2025 Qiagen NV Earnings Release
Similar to QGEN
ADC Therapeutics SA
New York Stock Exchange
Alto Neuroscience
New York Stock Exchange
Annovis Bio
New York Stock Exchange
Arcus Biosciences
New York Stock Exchange
Aurion Biotech
New York Stock Exchange
FAQ
As of Today at 22:47 UTC, shares in Qiagen NV are trading at $40.71. This share price information is delayed by 15 minutes.
Shares in Qiagen NV last closed at $40.71 and the price had moved by +3.79% over the past 365 days. In terms of relative price strength the Qiagen NV share price has underperformed the S&P500 Index by -2.41% over the past year.
The overall consensus recommendation for Qiagen NV is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreQiagen NV does not currently pay a dividend.
Qiagen NV does not currently pay a dividend.
Qiagen NV does not currently pay a dividend.
To buy shares in Qiagen NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $40.71, shares in Qiagen NV had a market capitalisation of $8.80bn.
Here are the trading details for Qiagen NV:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: QGEN
Based on an overall assessment of its quality, value and momentum Qiagen NV is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Qiagen NV is $49.71. That is 22.11% above the last closing price of $40.71.
Analysts covering Qiagen NV currently have a consensus Earnings Per Share (EPS) forecast of $2.29 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Qiagen NV. Over the past six months, its share price has outperformed the S&P500 Index by +4.93%.
As of the last closing price of $40.71, shares in Qiagen NV were trading -5.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Qiagen NV PE ratio based on its reported earnings over the past 12 months is 17.34. The shares last closed at $40.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Qiagen NV's management team is headed by:
- Lawrence Rosen - CSU
- Thierry Bernard - CEO
- Roland Sackers - CFO
- Metin Colpan - IND
- Ross Levine - IND
- Elaine Mardis - IND
- Elizabeth Tallett - IND
- Thomas Ebeling - SUB
- Toralf Haag - SUB